7-氯-6-氟-4-氧代-1H-喹啉-3-羧酸 | 88569-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-氯-6-氟-4-氧代-1H-喹啉-3-羧酸
• 英文名称: 7-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 7-chloro-6-fluoro-4(1H)-quinolone-3-carboxylic acid；7-chloro-6-fluoro-4-oxo-1H-quinoline-3-carboxylic acid
• CAS: 88569-32-8
• 化学式: C₁₀H₅ClFNO₃
• 分子量: 241.606
• InChiKey: FXPLBBILFCVNAA-UHFFFAOYSA-N

物化性质

• 熔点：
  285-287 °C(Solv: N,N-dimethylformamide (68-12-2))
• 沸点：
  401.7±45.0 °C(Predicted)
• 密度：
  1.627±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  7-氯-6-氟-4-氧代-1H-喹啉-3-羧酸 生成 7-chloro-6-fluoro-1H-quinolin-4-one
  参考文献：
  名称：

  Quinolone sulphonamides useful as antihypertensive agents

  摘要：

  具有降压活性的喹诺酮具有一般式I，其中X是可选择取代的苯环的残基；R是低碳烷基；R.sub.3是氢或低碳烷基；R.sub.1和R.sub.2，可以相同也可以不同，是氢、低碳烷基，或者与它们连接的氮原子一起形成一个含有氮、氧和硫的额外杂原子的5到7元饱和杂环环，可选择地由1个或多个低碳烷基取代；喹诺酮核的2和3位置之间的虚线代表一个可选键。这些化合物可用作降压剂。它们还适用于治疗心力衰竭和缺血性心脏病。除了三种化合物1-甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺、1,N-二甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺和6,7-二甲氧基甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺之外，一般式I的喹诺酮是新颖的。描述了含有一般式I化合物的制药组合物。还描述了制备新型喹诺酮的方法。

  公开号：

  US04772614A1
• 作为产物：
  描述：

  3-氯-4-氟苯胺 在 sodium hydroxide 作用下， 以 甲醇 、 二苯醚 为溶剂， 反应 7.0h， 生成 7-氯-6-氟-4-氧代-1H-喹啉-3-羧酸
  参考文献：
  名称：

  4-喹诺酮-3-羧酸衍生物的互变异构和酸度

  摘要：

  已经研究了4-喹诺酮-3-羧酸衍生物中的质子互变异构，特别强调了环取代基对平衡的影响。所用的技术包括UV，1 H-NMR，13 C-NMR（溶液和13 C-NMR CP / MAS（固态）和半经验和从头计算。的PK一个一些喹诺酮衍生物的值已被测定，并与相关的从半经验方法获得的数据。

  DOI：

  10.1016/s0040-4020(01)89860-4

文献信息

• Synthesis of 6-Fluoro-7-cyclic Amino-substituted Dicarboxylic Acid Quinolones and their Antibacterial Activity
  作者：A. Ravi Kumar、G. Sathaiah、A. Chandra Shekhar、K. Raju、P. Shanthan Rao、B. Narsaiah、Y. Kanaka Raju、U. S. N. Murthy、V. Srimai、M. Ramesh、T. Parthasarathy

  DOI：10.1002/jhet.1889

  日期：2014.8

  4-dihydroquinolone-3-carboxylic acids were synthesized as a new class of quinolones. Ethyl-6-fluoro-7-chloro-1,4-dihydro-4-quinoline-3-carboxylic acid was prepared from conventional method and reacted with ethyl bromoacetate to furnish N-carboxymethyl derivatives. The compounds were screed against various Gram-positive and Gram-negative bacterial strains. Antibacterial activity data is validated by molecular

  新型的1-羧甲基-6-氟-7-环氨基取代的4-氧代-1,4-二氢喹诺酮-3-羧酸 被合成为一类新的喹诺酮。用常规方法制备乙基-6-氟-7-氯-1,4-二氢-4-喹啉-3-羧酸溴乙酸乙酯提供N-羧甲基衍生物。将该化合物针对各种革兰氏阳性和革兰氏阴性细菌菌株进行熨平板。抗菌活性数据已通过分子对接研究得到验证。
• Quinolones having antihypertensive activity
  申请人：The Boots Company PLC

  公开号：EP0206616A2

  公开（公告）日：1986-12-30

  Quinolines with antihypertensive activity have the general formula 1, wherein X is the residue of an optionally substituted benzene ring; R is lower alkyl; R3 is hydrogen or lower alkyl; R1 and R2, which may be the same or different, are hydrogen, lower alkyl, or, together with the nitrogen atom to which they are attached, form a 5 to 7 membered saturated heterocyclic ring optionally containing an additional hetero atom selected from nitrogen, oxygen and sulphur and optionally substituted by 1 or more lower alkyl groups; and the dotted line between positions 2 and 3 of the quinolone nucleus represents an optional bond. The compounds are useful as antihypertensive agents. They are also indicated for use in treating heart failure and ischaemic heart disease. With the exception of the three compounds 1-methyl-4--oxo-1,4-dihydroquinoline-3-sulphonamide, 1,N-dimethyl-4--oxo-1,4-dihydroquinoline-3-sulphonamide and 6,7-dimeth- oxyl-methyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide, the quinolones of formula I are novel. Pharmaceutical compositions containing the compounds of formula I are described. Processes for preparing the novel quinolones are also described.

  具有抗高血压活性的喹啉类化合物具有通式 1、 其中，X 是任选取代的苯环的残基；R 是低级烷基；R3 是氢或低级烷基；R1 和 R2（可以相同或不同）是氢、低级烷基，或与它们连接的氮原子一起形成 5 至 7 个成员的饱和杂环，其中任选含有一个选自氮、氧和硫的杂原子，并任选被 1 个或多个低级烷基取代；喹诺酮核的位置 2 和 3 之间的虚线代表任选键。这些化合物可用作降压药。它们还可用于治疗心力衰竭和缺血性心脏病。 除了 1-甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺、1,N-二甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺和 6,7-二甲基-氧代-4-甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺这三种化合物外，式 I 中的喹诺酮类化合物均为新型化合物。 描述了含有式 I 化合物的药物组合物。还描述了制备新型喹诺酮类药物的工艺。
• 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0230053A2

  公开（公告）日：1987-07-29

  7-(substituted)piperazinyl-1-ethyl-6-fluoro-4-oxo-3-quinolinecarboxylic acids, the pharmacologically acceptable salts thereof, compositions containing them, processes and intermediates for producing them, and methods of using them to treat bacterial infections in warm-blooded animals.

  7-(取代)哌嗪基-1-乙基-6-氟-4-氧代-3-喹啉羧酸、其药理上可接受的盐、含有它们的组合物、生产它们的工艺和中间体，以及用它们治疗温血动物细菌感染的方法。
• Cruz, A. de la; Elguero, J.; Goya, P., Journal of Chemical Research, Miniprint, 1992, # 7, p. 1682 - 1693
  作者：Cruz, A. de la、Elguero, J.、Goya, P.、Martinez, A.、Gotor, V.、et al.

  DOI：——

  日期：——
• Synthesis and in vitro antiplasmodial activities of fluoroquinolone analogs
  作者：Sandeep K. Dixit、Nidhi Mishra、Manish Sharma、Shailja Singh、Alka Agarwal、Satish K. Awasthi、V.K. Bhasin

  DOI：10.1016/j.ejmech.2012.02.006

  日期：2012.5

  Fluoroquinolone analogs were synthesized by simple alkylation followed by click chemistry and evaluated for their antimalarial in vitro against chloroquine sensitive strain of Plasmodium falciparum while ciprofloxacin was used as standard. Our results showed that the compound 12 was found most active with IC50 value of 1.33 mu g/mL while ciprofloxacin showed IC50 = 8.81 mu g/mL. Therefore, screening of either known or unknown quinolone/fluoroquinolone analogs are worthwhile to find more potent antimalarial drugs which might prove useful in the treatment of mild or severe malaria in human either alone or in combination with existing antimalarial drugs. (C) 2012 Elsevier Masson SAS. All rights reserved.